If you’re a dividend investor prioritizing yield, consistency, and low volatility, this stock stands out as a strong candidate. Offering a forward dividend yield of 3.23%—well above the industry average—this healthcare devices leader is delivering stable income backed by an exceptional 40+ year history of uninterrupted dividend increases. Its risk profile is equally attractive, with a market-like beta of 0.82 and top-tier liquidity, helping to protect capital while supporting quick position adjustments. These attributes make it especially appealing for quality-focused investors seeking predictable returns in a volatile market environment.
The company operates in the global medical technology space, supplying essential therapeutic devices across cardiovascular, neurological, surgical, and metabolic care. Despite sector-wide challenges, it continues to expand through innovation in high-growth areas such as robotic surgery, advanced ablation, and neurostimulation platforms. However, risks remain—tariff exposure, foreign exchange fluctuations, and a complex spin-off strategy may constrain near-term earnings leverage. Still, the long-term fundamentals remain compelling, supported by steady organic growth and strong operational execution.
As healthcare innovation accelerates and demographic tailwinds increase demand for medical interventions, this stock is well-positioned for dependable performance. Whether you’re looking for insights into how the business balances yield with growth, or want to understand the implications of emerging industry risks, this deep-dive delivers the full picture.
Read on to see why we’ve reaffirmed this position in our Quality Dividends Portfolio—and what it means for your income strategy.
